US Targets KS International Traders and KS Pharmacy Owner in Executive Order 14367

(INDIA) — The US Department of State imposed visa restrictions on May 13, 2026, targeting the owner of KS International Traders, also known as KS Pharmacy, and 13 associated individuals over what it said was trafficking illicit fentanyl to the United States.

Tommy Pigott, a State Department spokesman, announced the action and said, “The US Department of State is taking steps to impose visa restrictions on 13 individuals associated with KS International Traders and its owner, which has sold counterfeit prescriptions laced with illicit fentanyl to unsuspecting Americans.”

Pigott tied the move to President Donald Trump’s Executive Order 14367 and said, “Those complicit in poisoning Americans will be denied entry to the United States.”

The restrictions were issued under INA § 212(a)(3)(C), a provision that renders inadmissible foreign nationals whose entry would have potentially serious adverse foreign policy consequences for the United States.

Pigott said the administration linked that authority to Executive Order 14367, which designates fentanyl as a “Weapon of Mass Destruction.” The order gave the announcement a national security frame, while the visa action itself focused on barring travel to the United States.

KS International Traders, an India-based online pharmacy also known as KS Pharmacy, allegedly sold “hundreds of thousands of counterfeit prescription pills laced with illicit fentanyl” to US customers. The operation generated revenue through trafficking networks involving partners in the United States and the Dominican Republic.

Officials said the pills were marketed as legitimate pharmaceuticals. They contained fentanyl, fentanyl analogues, and methamphetamine.

The State Department did not release the names of the 13 people covered by the new visa restrictions. The announcement identified the owner of KS International Traders as the central figure in the action, but it did not publish the full list of associated individuals.

Khizar Mohammad Iqbal Shaikh had already been named in earlier US sanctions tied to the same alleged network. On September 24, 2025, the Treasury Department’s Office of Foreign Assets Control designated Shaikh, Sadiq Abbas Habib Sayyed, and KS International Traders itself for supplying counterfeit fentanyl-laced pills.

That earlier action placed KS International Traders and KS Pharmacy inside a broader US sanctions campaign against suppliers accused of feeding fentanyl distribution chains. The new visa restrictions add an immigration penalty to measures that had already targeted the business and named associates.

Another set of related sanctions followed in April 2026, when OFAC sanctioned Satishkumar Hareshbhai Sutaria and salesperson Yuktakumari Ashishkumar Modi. US authorities said they operated through India-based SR Chemicals and Pharmaceuticals and Agrat Chemicals.

Officials said Sutaria and Modi facilitated shipments of fentanyl precursors to Mexico and Guatemala. Indian authorities arrested both in March 2025.

The visa restrictions carry consequences beyond denial of a single travel application. Under INA § 212(a)(3)(C), affected individuals are generally ineligible for US visas or admission.

That inadmissibility can last for life unless the Secretary of State determines that entry would serve US interests. That is a discretionary waiver and is rarely granted in narcotics-related cases.

In practice, the State Department’s use of that section places those named in a category that reaches both visa issuance and entry at the border. A person affected by the restriction can face exclusion even before any separate immigration process begins.

The legal basis also gives the executive branch wide room to act. The restrictions reflect binding executive authority and do not require judicial review.

That makes the State Department announcement more than a diplomatic rebuke. It is an immediate immigration consequence tied to alleged fentanyl trafficking and supported by presidential authority that the department linked to Executive Order 14367.

The case also shows how narcotics enforcement, sanctions policy, and visa law now overlap in a single response. Treasury designated people and companies tied to the alleged trade; State then moved to cut off access to the United States through visa restrictions.

US officials described the alleged conduct in stark terms. Pigott said the measures targeted people associated with a company that sold fentanyl-laced counterfeit prescriptions to “unsuspecting Americans.”

The State Department’s language focused on the pills as fake versions of legitimate medicine rather than openly marketed street drugs. That detail matters in the government account because it places the alleged trafficking inside online pharmaceutical sales, where buyers may believe they are purchasing standard prescription products.

Authorities said the operation reached US consumers while drawing support from partners in the Dominican Republic. The announcement did not break out what role each country-based partner allegedly played, but it identified a cross-border network rather than a single local seller.

Mexico and Guatemala appeared in the related sanctions tied to precursor shipments. India appeared in both strands of the case, first through KS International Traders and later through SR Chemicals and Pharmaceuticals and Agrat Chemicals.

Those details place the State Department move inside a wider campaign against supply chains rather than one isolated shipment. The US government’s actions named an online pharmacy, an owner, associates, precursor suppliers, and linked business entities across several countries.

Even so, the visa announcement remained tightly drawn in one respect: it did not identify the 13 associated individuals. That leaves the formal scope of the travel restrictions public in number, but not in names.

People seeking to challenge such a decision face narrow options. A mandamus action in federal court is one possible route, citing the District of Columbia Circuit as having jurisdiction over State Department visa decisions.

Mandamus is a court order request that asks a judge to compel a government official or agency to perform a duty. In this context, it is a possible procedural challenge, even though the visa restrictions themselves stem from executive authority that does not require judicial review.

That split is central to how the measure operates. The administration can impose the restriction through immigration and foreign policy powers, while any later court fight would focus on process and agency action rather than relitigating the government’s broader anti-fentanyl policy.

The State Department’s announcement did not attach the visa action to a criminal indictment or trial. It rested instead on inadmissibility authority under INA § 212(a)(3)(C), the alleged trafficking conduct, and the administration’s treatment of fentanyl under Executive Order 14367.

Shaikh, Sayyed, Sutaria, and Modi are the only individuals identified by name in the material tied to the broader sanctions picture. KS International Traders, KS Pharmacy, SR Chemicals and Pharmaceuticals, and Agrat Chemicals are the entities named.

By combining sanctions designations with visa bans, US authorities have moved against both commercial access and physical entry. Pigott’s closing line framed that aim in blunt terms: “Those complicit in poisoning Americans will be denied entry to the United States.”